Author:
Casadei Gardini Andrea,Aquilina Michele,Oboldi Devil,Lucchesi Alessandro,Carloni Silvia,Tenti Elena,Burgio Marco Angelo,Amadori Dino,Frassineti Giovanni Luca
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference16 articles.
1. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996, 73: 101-105. 10.1038/bjc.1996.18.
2. Abbratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA: Efficacy and safety profile of gemcitabine in non-smallcell lung cancer: a phase II study. J Clin Oncol. 1994, 12: 1535-1540.
3. Coskun U, Günel N, Yildirim Y: Gemcitabine induced pulmonary injury. Case Rep Pract Rev. 2004, 5: 178-179.
4. Remuzzi G, Schieppati A, Ruggenenti P, Bertani T: Thrombotic thrombocytopenia purpura, hemolytic uremic syndrome, and acute cortical necrosis. Diseases of the Kidney. Edited by: Schrier RW, Gottschalk CW. 1993, Boston: Little, Brown and Company, 2063-2094. 5
5. Hosein PJ, Jr G, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR, Rocha Lima CM: A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. J Clin Oncol. 2013, 36: 151-156. 10.1097/COC.0b013e3182436e8c.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献